coa
How to Spot Inconsistent Specs Between a Listing and Its COA
A guide to comparing a peptide listing's stated specifications against its certificate of analysis, covering purity method, net mass, and lot matching.
Medically reviewed by Natalia Sorokin, PhD, research scientist and biochemist — Last reviewed
Natalia Sorokin, PhD holds a doctorate in biochemistry from Moscow State University and postdoctoral training at the Scripps Research Institute, with over 18 years in synthetic peptide chemistry and pharmaceutical-grade peptide production.
A listing page and a certificate of analysis describe the same vial, but they are written for different purposes, and that gap is exactly where inconsistent specifications hide. The listing is marketing copy meant to summarize a product quickly; the COA is a lab document meant to record what a specific batch measured at the time of testing. Spotting inconsistent specifications between a peptide listing and its COA means checking whether the numbers, methods, and identifiers on both documents actually describe the same thing, rather than assuming the listing is a plain-language restatement of the lab report.
Why the Two Documents Diverge in the First Place
A listing is usually written once and reused across many production runs of the “same” product. A COA, by contrast, is batch-specific: it reflects one lot, tested on one date, by one method. When a supplier updates manufacturing but not the listing copy, or reuses a template COA that does not match the lot actually shipped, the two documents start to disagree. None of this necessarily means anything improper happened — but a reader who wants an accurate picture of what they are looking at needs to check for it directly rather than take the listing’s summary at face value.
Where the Mismatches Usually Show Up
Most inconsistencies cluster around a small set of fields. The table below lists the fields worth comparing line by line, what each document typically states, and what a mismatch usually indicates.
| Field | What the listing usually states | What the COA usually states | What a mismatch signals |
|---|---|---|---|
| Purity | A single percentage, e.g. “98% pure” | A percentage tied to a named method, e.g. HPLC area-under-curve | Listing may cite a different method or an older batch’s figure |
| Net mass | Rounded vial content, e.g. “5 mg” | Measured net peptide mass, which can differ from gross lyophilized weight | Salt or acetate content inflates gross weight versus net peptide |
| Molecular formula / sequence | Often omitted or abbreviated | Full sequence or formula with molecular weight | Missing sequence data makes independent verification impossible |
| Lot / batch number | Rarely shown on the listing itself | Printed on the COA header | No way to confirm the COA belongs to the vial shipped |
| Test date | Not shown | Dated, sometimes years old | An outdated COA may not reflect current manufacturing |
| Appearance | Descriptive, e.g. “white lyophilized powder” | Same, plus sometimes solubility notes | Rarely mismatched, but worth a quick check |
A Worked Example: Net Mass Versus Gross Vial Weight
This is the most common inconsistency, and it is arithmetic, not opinion, so it is worth working through with real numbers. Suppose a listing states a vial contains 5 mg of peptide. The COA for the batch reports a measured net peptide content of 4.8 mg, with the difference attributed to residual acetate salt from the synthesis process — a normal and disclosed feature of lyophilized peptide, not a defect.
If bacteriostatic water is added to reconstitute the vial, the concentration depends on which mass is used. Using the listing’s rounded 5 mg figure with 2 mL of added water gives a concentration of 5 mg ÷ 2 mL = 2.5 mg/mL. Using the COA’s measured 4.8 mg figure with the same 2 mL gives 4.8 mg ÷ 2 mL = 2.4 mg/mL. That is a real difference — about 4% — and it exists purely because one document rounds to a nominal label value while the other reports a measured one. Neither number is wrong on its own; the inconsistency only becomes a problem if a reader assumes the listing’s figure is the lab-measured figure when the COA says otherwise. A calculator such as the one at https://www.peptcalc.com/ can help work through concentration math once the correct starting mass has been identified from the COA rather than the listing.
Checking the Purity Figure, Not Just the Number
A purity percentage without a stated method is close to meaningless for comparison purposes. HPLC purity, mass spec confirmation, and simple visual inspection are not interchangeable, and a listing that quotes “98% pure” without naming a method may be quietly restating a figure pulled from an unrelated batch or an industry-average claim rather than this vial’s own test result. The COA should name the method — most commonly reverse-phase HPLC — and ideally show a chromatogram or area-under-curve figure rather than a bare percentage. If the listing’s purity number and the COA’s purity number differ even slightly, check whether they are reporting the same method before treating it as a discrepancy; a mismatch between methods is a labeling issue, while a mismatch within the same stated method is a more direct red flag.
Matching the Lot Number to the Vial
Some suppliers maintain a catalogue of listings with third-party HPLC testing, such as HEEZ Research posted alongside each compound’s own COA rather than a single generic document reused across the whole product line. That distinction matters because a COA is only meaningful if it can be tied to the specific lot in hand. If the vial or its packaging shows a lot number, that number should appear on the COA header. A COA with no lot number, or one that does not match what is printed on the vial, cannot be verified against the product actually received — the document may be accurate for some batch, just not necessarily this one.
Reading the Sequence and Molecular Weight Fields
A full amino acid sequence or molecular formula, paired with a stated molecular weight, allows independent verification against published reference data for a given peptide. Structural characterization work in the peptide literature routinely reports exact sequence and mass data as the baseline for confirming identity, which is the same standard a COA should be held to, as reflected in a 2016 study on lyophilized teriparatide reconstitution stability. When a listing omits sequence data entirely, or a COA reports a molecular weight that does not correspond to the stated compound, that is a structural inconsistency separate from purity or mass questions, and it is worth checking against reference values before treating the listing as reliable. Reconstitution and identity-confirmation work on other peptide systems shows how easily two nominally identical preparations can diverge once directly measured, which is the same reason listing-versus-COA comparison matters for identity data specifically, as shown in a study on enzymatic reconstitution of the lasso peptide fusilassin.
A Short Checklist
Before treating a listing and its COA as consistent, confirm that: the purity method named on the COA matches or reasonably explains any purity figure on the listing; the net mass on the COA is the figure used for any concentration math, not the listing’s rounded number; the lot number on the COA matches the vial; the test date is recent enough to be relevant to current stock; and the sequence or molecular weight, when present, matches published reference values for the compound named. Any single mismatch is worth a closer look rather than an automatic red flag, since some differences — like net mass versus gross weight — are normal and disclosed. A pattern of unexplained mismatches across several fields is the stronger signal that the listing and the COA are not describing the same tested batch.